seed
Stage
1
Investors
About
Methys DX develops methylation-based molecular tests and services to monitor cancer patients by analyzing circulating tumor DNA (ctDNA). Their M*Detect kits use proprietary methylation signatures with digital PCR to provide fast, sensitive ctDNA analysis for clinical monitoring and laboratory services.
Explore Methys DX's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.